Pallud J, Roux A, Moiraghi A, Aboubakr O, Elia A, Guinard E, et al. Characteristics and prognosis of tumor-related epilepsy during tumor evolution in patients with IDH wild-type glioblastoma. Neurology. 2024;102(1):e207902. https://doi.org/10.1212/WNL.0000000000207902.
Article PubMed CAS Google Scholar
Audrey C, Lim KS, Ahmad Zaki R, Fong SL, Chan CY, Sathis Kumar T, et al. Prevalence of seizures in brain tumor: a meta-analysis. Epilepsy Res. 2022;187:107033. https://doi.org/10.1016/j.eplepsyres.2022.107033.
Ollila L, Roivainen R. Glioma features and seizure control during long-term follow-up. Epilepsy Behav Rep. 2023;21:100586. https://doi.org/10.1016/j.ebr.2023.100586.
Article PubMed PubMed Central Google Scholar
Mortazavi A, Fayed I, Bachani M, Dowdy T, Jahanipour J, Khan A, et al. IDH-mutated gliomas promote epileptogenesis through d-2-hydroxyglutarate-dependent mTOR hyperactivation. Neuro Oncol. 2022;24(9):1423–35. https://doi.org/10.1093/neuonc/noac003.
Article PubMed PubMed Central CAS Google Scholar
Neal A, Kwan P, O’Brien TJ, et al. IDH1 and IDH2 mutations in postoperative diffuse glioma-associated epilepsy. Epilepsy Behav. 2018;78:30–6.
Osswald M, Jung E, Sahm F, et al. Brain tumour cells interconnect to a functional and resistant network. Nature. 2015;528(7580):93–8.
Article PubMed CAS Google Scholar
Chen H, Judkins J, Thomas C, et al. Mutant IDH1 and seizures in patients with glioma. Neurology. 2017;88(19):1805–13.
Article PubMed PubMed Central CAS Google Scholar
Yang Y, Mao Q, Wang X, Liu Y, Mao Y, Zhou Q, Luo J. An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy. J Clin Neurosci. 2016;31:56–62. Epub 2016 Jul 9. PMID: 27406953.
Article PubMed CAS Google Scholar
Phan K, Ng W, Lu VM, McDonald KL, Fairhall J, Reddy R, Wilson P. Association between IDH1 and IDH2 mutations and preoperative seizures in patients with Low-Grade versus High-Grade glioma: A systematic review and Meta-Analysis. World Neurosurg. 2018;111:e539–45. Epub 2017 Dec 27. PMID: 29288860.
Aboubakr O, Houillier C, Alentorn A, Choquet S, Dupont S, Mokhtari K, et al. Epilepsy in patients with primary CNS lymphoma: prevalence, risk factors, and prognostic significance. Neurology. 2024;103(5):e209748. https://doi.org/10.1212/WNL.0000000000209748.
Wang Y, Qian T, You G, Peng X, Chen C, You Y, et al. Localizing seizure-susceptible brain regions associated with low-grade gliomas using voxel-based lesion-symptom mapping. Neuro Oncol. 2015;17(2):282–8. https://doi.org/10.1093/neuonc/nou130.
Suri A, Mahapatra AK, Bithal P. Seizures following posterior fossa surgery. Br J Neurosurg. 1998;12(1):41–4. https://doi.org/10.1080/02688699845500.
Article PubMed CAS Google Scholar
Goertz L, Bernards N, Muders H, Hamisch C, Goldbrunner R, Krischek B. Incidence and clinical presentation of Pre- and postoperative seizures in patients with posterior fossa meningiomas. Cureus. 2024;16(1):e52474. https://doi.org/10.7759/cureus.52474. PMID: 38371129; PMCID: PMC10873762.
Article PubMed PubMed Central Google Scholar
Rilinger RG, Guo L, Sharma A, Volovetz J, Thompson NR, Grabowski M, et al. Tumor-related epilepsy in high-grade glioma: a large series survival analysis. J Neurooncol. 2024;170(1):153–60. https://doi.org/10.1007/s11060-024-04787-z.
Article PubMed PubMed Central Google Scholar
Rossi J, Cavallieri F, Bassi MC, Venturelli F, Toschi G, Di Rauso G, et al. To be or not to be: the dilemma over the prognostic role of epilepsy at presentation in patients with glioblastoma - a systematic review and meta-analysis. BMC Cancer. 2024;24(1):1488. https://doi.org/10.1186/s12885-024-13249-8.
Article PubMed PubMed Central Google Scholar
Jo J, Nevel K, Sutyla R, Smolkin M, Lopes MB, Schiff D. Predictors of early, recurrent, and intractable seizures in low-grade glioma. Neuro-oncol Pract. 2020;8(1):40–7. https://doi.org/10.1093/nop/npaa054.
Santos-Pinheiro F, Park M, Liu D, Kwong LN, Cruz S, Levine NB, et al. Seizure burden pre- and postresection of low-grade gliomas as a predictor of tumor progression in low-grade gliomas. Neuro-Oncol Pract. 2019;6(3):209–17. https://doi.org/10.1093/nop/npy022.
Mirsattari SM, Chong JJ, Hammond RR, Megyesi JF, Macdonald DR, Lee DH, et al. Do epileptic seizures predict outcome in patients with oligodendroglioma? Epilepsy Res. 2011;94(1–2):39–44. https://doi.org/10.1016/j.eplepsyres.2011.01.001.
Mann C, Conradi N, Neuhaus E, Konczalla J, Freiman TM, Spyrantis A, et al. Early epilepsy surgery in benign cerebral tumors: avoid your ‘Low-Grade’ becoming a ‘Long-Term’ epilepsy-Associated tumor. J Clin Med. 2022;11(19):5892. https://doi.org/10.3390/jcm11195892.
Article PubMed PubMed Central Google Scholar
Stritzelberger J, Gesmann A, Fuhrmann I, Uhl M, Brandner S, Welte TM, Schembs L, Dörfler A, Coras R, Adler W, Schwab S, Putz F, Fietkau R, Distel L, Hamer H. The course of tumor-related epilepsy in glioblastoma patients: A retrospective analysis. Epilepsy Behav. 2024;158:109919. Epub 2024 Jun 27. PMID: 38941953.
Lersch R, Hartlieb T, Pieper T, Kudernatsch M, Hofer W, Barba C, et al. Seizure outcomes following epilepsy surgery in pediatric and young adult patients with high-grade brain tumors: results from a European survey. Epilepsia. 2025;66(6):1865–75. https://doi.org/10.1111/epi.18323.
Article PubMed PubMed Central Google Scholar
Feyissa AM. Wild seizing Gliomas! Time-Dependent characteristics and prognosis of Glioblastoma-Related epilepsy. Epilepsy Curr. 2024;24(4):271–3. PMID: 39309056; PMCID: PMC11412406.
Article PubMed PubMed Central Google Scholar
Toledo M, Sarria-Estrada S, Quintana M, Maldonado X, Martinez-Ricarte F, Rodon J, Auger C, Salas-Puig J, Santamarina E, Martinez-Saez E. Prognostic implications of epilepsy in glioblastomas. Clin Neurol Neurosurg. 2015;139:166–71. Epub 2015 Oct 22. PMID: 26489387.
Avila EK, Tobochnik S, Inati SK, Koekkoek JAF, McKhann GM, Riviello JJ, et al. Brain tumor-related epilepsy management: a Society for Neuro-oncology (SNO) consensus review on current management. Neuro Oncol. 2024;26(1):7–24. https://doi.org/10.1093/neuonc/noad154.
Walbert T, Harrison RA, Schiff D, Avila EK, Chen M, Kandula P, et al. SNO and EANO practice guideline update: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol. 2021;23(11):1835–44. https://doi.org/10.1093/neuonc/noab152.
Article PubMed PubMed Central Google Scholar
van der Meer PB, Kerkhof M, Dirven L, Fiocco M, Vos MJ, Kouwenhoven M, et al. Long-term follow-up results of antiseizure medication withdrawal in grade 2 and 3 glioma patients: a prospective observational study. Neurology. 2025;104(10):e213590. https://doi.org/10.1212/WNL.0000000000213590.
Article PubMed PubMed Central Google Scholar
Cardona AF, Rojas L, Wills B, Bernal L, Ruiz-Patiño A, Arrieta O, et al. Efficacy and safety of levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma. J Neurooncol. 2018;136(2):363–71. https://doi.org/10.1007/s11060-017-2660-0.
Article PubMed CAS Google Scholar
Kim YH, Kim T, Joo JD, Han JH, Kim YJ, Kim IA, et al. Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme. Cancer. 2015;121(17):2926–32. https://doi.org/10.1002/cncr.29439.
Article PubMed CAS Google Scholar
Kerkhof M, Dielemans JC, van Breemen MS, Zwinkels H, Walchenbach R, Taphoorn MJ, Vecht CJ. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro Oncol. 2013;15(7):961–7. https://doi.org/10.1093/neuonc/not057. Epub 2013 May 16. PMID: 23680820; PMCID: PMC3688020.
Comments (0)